Geron Corporation (GERN): Price and Financial Metrics


Geron Corporation (GERN): $1.23

0.01 (+0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GERN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 500

in industry

GERN POWR Grades


  • GERN scores best on the Momentum dimension, with a Momentum rank ahead of 34.68% of US stocks.
  • The strongest trend for GERN is in Growth, which has been heading down over the past 31 weeks.
  • GERN ranks lowest in Value; there it ranks in the 6th percentile.

GERN Stock Summary

  • With a price/sales ratio of 1,225.26, Geron Corp has a higher such ratio than 99.35% of stocks in our set.
  • With a year-over-year growth in debt of 397.36%, Geron Corp's debt growth rate surpasses 96.82% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GERN comes in at -44.41% -- higher than that of just 6.4% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Geron Corp are MRSN, CKPT, AIM, EDSA, and CRDF.
  • GERN's SEC filings can be seen here. And to visit Geron Corp's official web site, go to www.geron.com.

GERN Valuation Summary

  • GERN's price/sales ratio is 1216; this is 33677.78% higher than that of the median Healthcare stock.
  • GERN's price/earnings ratio has moved up 2.6 over the prior 243 months.
  • GERN's price/sales ratio has moved up 1170.2 over the prior 243 months.

Below are key valuation metrics over time for GERN.

Stock Date P/S P/B P/E EV/EBIT
GERN 2020-02-06 400.2 1.7 -5.7 -5.2
GERN 2018-01-03 310.8 2.8 -10.4 -10.1
GERN 2015-10-07 427.0 4.1 -12.9 -12.5
GERN 2009-09-14 431.0 3.5 -9.3 -7.9
GERN 2005-12-08 103.5 3.0 -17.4 -14.1
GERN 2002-01-24 43.9 4.4 -5.4 -5.6

GERN Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at -177.85%.
  • Its year over year cash and equivalents growth rate is now at 55.13%.
  • Its 4 year net income to common stockholders growth rate is now at -14520.81%.
GERN's revenue has moved down $542,000 over the prior 34 months.

The table below shows GERN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 0.338 -73.192 -87.086
2020-12-31 0.253 -66.652 -75.617
2020-09-30 0.374 -64.404 -80.9
2020-06-30 0.397 -60.935 -76.429
2020-03-31 0.455 -57.285 -74.844
2019-12-31 0.46 -43.829 -68.548

GERN Price Target

For more insight on analysts targets of GERN, see our GERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.4 (Strong Buy)

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $1.23 52-week high $2.36
Prev. close $1.22 52-week low $1.20
Day low $1.22 Volume 227,480
Day high $1.24 Avg. volume 5,601,758
50-day MA $1.40 Dividend yield N/A
200-day MA $1.63 Market Cap 390.25M

Geron Corporation (GERN) Company Bio


Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.


GERN Latest News Stream


Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream


Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on July 21, 2021 at an exercise price of $1.33 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock options have a 10

Business Wire | July 22, 2021

Return On Capital Employed Overview: Geron

During Q1, Geron ''s (NASDAQ: GERN ) reported sales totaled $137.00 thousand. Despite a 22.3% in earnings, the company posted a loss of $28.45 million. Geron collected $50.00 thousand in revenue during Q4, but reported earnings showed a $23.27 million loss. What Is ROCE? Changes in earnings and sales indicate shifts in Geron''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com

Benzinga | June 24, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and let's get ready to for another busy week of trading.

William White on InvestorPlace | June 21, 2021

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

Yahoo | June 21, 2021

Read More 'GERN' Stories Here

GERN Price Returns

1-mo -15.75%
3-mo -10.22%
6-mo -41.43%
1-year -22.64%
3-year -64.45%
5-year -55.76%
YTD -22.64%
2020 16.91%
2019 36.00%
2018 -44.44%
2017 -13.04%
2016 -57.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8463 seconds.